Twist Bioscience (NASDAQ:TWST) is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.
At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides. These products support applications across research, drug discovery, diagnostic development, and synthetic biology. By combining microfluidics, proprietary software, and chip-based synthesis, the company claims enhanced accuracy and uniformity while driving down per-base costs. Twist also offers next-generation sequencing services and bioinformatics support to accelerate customer workflows.
Twist Bioscience serves a global customer base spanning pharmaceutical and biotechnology companies, academic and government research institutions, agricultural and industrial biotechnology firms, and emerging data-storage ventures exploring DNA as a long-term archival medium. In addition to its primary manufacturing facility in California, the company has expanded operations to Europe, enabling faster delivery and localized support in key markets.
Leadership at Twist is anchored by co-founder and Chief Executive Officer Dr. Emily Leproust, whose background in chemistry and experience at leading genomics organizations helped shape the company’s technology strategy. Under her guidance, Twist has grown from a single R&D lab to a public company focused on scaling DNA synthesis for a wide range of commercial applications.
